Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
57
PRAX Quote, Financials, Valuation and Earnings
Last price:
$274.43
Seasonality move
:
19.37%
Day range:
$274.07 - $286.50
52-week range:
$26.70 - $286.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
780.38x
P/B ratio:
20.07x
Volume:
405.2K
Avg. volume:
951.9K
1-year change:
255.46%
Market cap:
$6.9B
Revenue:
$8.6M
EPS (TTM):
-$12.90
Analysts' Opinion
-
Consensus RatingPraxis Precision Medicines, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 0 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $419.13, Praxis Precision Medicines, Inc. has an estimated upside of 52.01% from its current price of $275.73.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $83.00 representing 100% downside risk from its current price of $275.73.
Fair Value
-
According to the consensus of 13 analysts, Praxis Precision Medicines, Inc. has 52.01% upside to fair value with a price target of $419.13 per share.
PRAX vs. S&P 500
-
Over the past 5 trading days, Praxis Precision Medicines, Inc. has underperformed the S&P 500 by -1.52% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Praxis Precision Medicines, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Praxis Precision Medicines, Inc. revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Praxis Precision Medicines, Inc. reported revenues of --.
Earnings Growth
-
Praxis Precision Medicines, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Praxis Precision Medicines, Inc. reported earnings per share of -$3.36.
Enterprise value:
6.6B
EV / Invested capital:
19.27x
Price / LTM sales:
780.38x
EV / EBIT:
--
EV / Revenue:
888.18x
PEG ratio (5yr expected):
-0.84x
EV / Free cash flow:
-28.97x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$7.3M
Return On Assets:
-61.29%
Net Income Margin (TTM):
-3658.53%
Return On Equity:
-67.75%
Return On Invested Capital:
-67.57%
Operating Margin:
-856.97%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.9M | $1.6M | $7.5M | $302K | -- | |
| Gross Profit | $691K | $1.2M | $7.3M | $210K | -$19K | |
| Operating Income | -$140M | -$164M | -$293.1M | -$56.8M | -$78.4M | |
| EBITDA | -$138.8M | -$163.6M | -$293M | -$56.7M | -$78.3M | |
| Diluted EPS | -$33.66 | -$10.30 | -$12.90 | -$2.75 | -$3.36 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $319.3M | $132.3M | $103.3M | $360M | $273.8M | |
| Total Assets | $324.4M | $136.9M | $106.7M | $416.3M | $396.4M | |
| Current Liabilities | $24.8M | $29M | $16.8M | $32.9M | $52.9M | |
| Total Liabilities | $28.5M | $31.7M | $20M | $33.6M | $52.9M | |
| Total Equity | $295.9M | $105.2M | $86.8M | $382.7M | $343.5M | |
| Total Debt | $3.7M | $2.8M | $1.7M | $436K | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$115.1M | -$98.4M | -$228.8M | -$27.2M | -$64.7M | |
| Cash From Investing | $61.6M | -$237.6M | $6.3M | $49.6M | $50.4M | |
| Cash From Financing | $92.2M | $403.6M | $203.3M | $1.2M | $6.4M | |
| Free Cash Flow | -$115.1M | -$98.5M | -$228.8M | -$27.2M | -$64.7M | |
PRAX
Sector
Market Cap
$6.9B
$28.1M
Price % of 52-Week High
96.24%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-18.23%
-1.49%
1-Year Price Total Return
255.46%
-17.13%
Beta (5-Year)
2.946
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$272.99
200-day SMA
Buy
Level
$82.55
Bollinger Bands (100)
Buy
Level
40.01 - 207.41
Chaikin Money Flow
Sell
Level
-511.2K
20-day SMA
Buy
Level
$239.94
Relative Strength Index (RSI14)
Buy
Level
68.60
ADX Line
Buy
Level
16.41
Williams %R
Sell
Level
-10.2013
50-day SMA
Buy
Level
$199.96
MACD (12, 26)
Buy
Level
67.75
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Neutral
Level
999.7K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (20.9512)
Sell
CA Score
(Annual)
Level (-1.7685)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (7.5491)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, PRAX has received 12 Buy ratings 0 Hold ratings, and 1 Sell ratings. The PRAX average analyst price target in the past 3 months is $419.13.
-
Where Will Praxis Precision Medicines, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Praxis Precision Medicines, Inc. share price will rise to $419.13 per share over the next 12 months.
-
What Do Analysts Say About Praxis Precision Medicines, Inc.?
Analysts are divided on their view about Praxis Precision Medicines, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Praxis Precision Medicines, Inc. is a Sell and believe this share price will drop from its current level to $83.00.
-
What Is Praxis Precision Medicines, Inc.'s Price Target?
The price target for Praxis Precision Medicines, Inc. over the next 1-year time period is forecast to be $419.13 according to 13 Wall Street analysts, 12 of them rate the stock a Buy, 1 rates the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PRAX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Praxis Precision Medicines, Inc. is a Buy. 12 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PRAX?
You can purchase shares of Praxis Precision Medicines, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Praxis Precision Medicines, Inc. shares.
-
What Is The Praxis Precision Medicines, Inc. Share Price Today?
Praxis Precision Medicines, Inc. was last trading at $274.43 per share. This represents the most recent stock quote for Praxis Precision Medicines, Inc.. Yesterday, Praxis Precision Medicines, Inc. closed at $275.73 per share.
-
How To Buy Praxis Precision Medicines, Inc. Stock Online?
In order to purchase Praxis Precision Medicines, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PRAX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PRAX
Sector
P/E ratio
--
23.89x
PEG ratio
-0.84x
-0.01x
P/B ratio
20.07x
1.81x
Price / LTM sales
780.38x
1.59x
Growth Metrics
PRAX
Sector
Revenue growth
-100%
4.62%
Earnings growth
-22.38%
11.06%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$3.49
-$0.21
Profitability
PRAX
Sector
Profitability FY 2024
$8.2M
$3.6M
Return on invested capital
-67.57%
-31.84%
Return on assets
-61.29%
-27.96%
Return on equity
-67.75%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
4
Balance Sheet
PRAX
Sector
Total cash
$267.2M
$26.4M
Short term investments
$177.2M
$25.7M
Total assets
$483.1M
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
Sell
32
SMX alert for Dec 24
SMX (Security Matters) Plc [SMX] is down 8.94% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
